Recent Updates
Recently added Catalysts

BHB-1893

Phase 3

Cardiomyopathy, Hypertrophic Obstructive | Small molecule | Cardiovascular |Braveheart Bio, Inc.|Trials Updated: Oct 2, 2026

BHB-1893 development status

Highest phase Phase 3
Registered trials 1 across 1 sponsor since Aug 2026

BHB-1893 target and mechanism

Molecular targetcardiac myosin
Target classProtein
ModalitySmall molecule

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindACTIVE_CONTROLLEDDMC
Total Trials1
Total Enrollment210

FDA Designations

No designations recorded

BHB-1893 clinical trials

BHB-1893 · 1 trial · 1 indication

Phase 3 1
NCT07755904BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic CardiomyopathyCardiomyopathy, Hypertrophic Obstructive
RECRUITING210 Analytics
PHASE3RECRUITING
BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic Cardiomyopathy
Cardiomyopathy, Hypertrophic Obstructive
NCT07755904210
Unlock trial analytics

Study Endpoints

Primary Endpoints

Change from Baseline in Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise Testing (CPET)
Baseline, Week 24

Secondary Endpoints

Change from Baseline in Valsalva Left Ventricular Outflow Tract Gradient (LVOT-G)
Baseline, Week 24
Number of Participants with >=1 Class Improvement in New York Heart Association (NYHA) Class
Baseline to Week 24
Change from Baseline in Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score (KCCQ-CSS)
Baseline, Week 24
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
BHB-1893EXPERIMENTALParticipants will receive BHB-1893 twice daily and matching placebo for metoprolol once daily.
MetoprololACTIVE_COMPARATORParticipants will receive metoprolol once daily and matching placebo for BHB-1893 twice daily.

Interventions

NameTypeDescription
BHB-1893DRUGTablets for oral use
MetoprololDRUGCapsules for oral use
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 85 Years
SexALL
Healthy VolunteersNo
Study Sites3

Key Inclusion Criteria: * Diagnosed with oHCM per the protocol specified criteria * NYHA Class II or III at screening visits * KCCQ-CSS that meets the protocol specified criteria at screening visits * Adequate acoustic windows for echocardiography Key Exclusion Criteria: * Medical indication for ...

Countries:United States
Unlock Eligibility Criteria

Other drugs targeting cardiac myosin

MYK-224 BMY· PHASE1 Aficamten CYTK· PHASE3 CK-3773274 CYTK· PHASE2 CK-4021586 CYTK· PHASE2

Explore more on BiopharmaWatch

Braveheart Bio, Inc. (BRVE)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with BCompanies A to ZEvery biotech and pharma company we track